1. Strengthening the Outsource Service Offering through Integration

    Controlling costs and increasing efficiencies are two fundamental drivers for outsourcing of pharmaceutical manufacturing, explains Luigi Trussardo, CEO of Olon Ricerca Bioscience.

  2. Meeting Biopharma Contract Manufacturing Needs with a Flexible Global Network

    Gustavo Mahler, President & CEO of AGC Biologics discusses the increasing need for CDMO support to provide with advanced capabilities and technology platforms across scales and geographies. 

    President & CEOAGC Biologics
  3. Creating Comprehensive Solutions through Laboratory Testing

    Xin Zhang, Ph.D., Vice President & Global Head of DMPK, Bioanalysis & Abgent, Eugene Gong, Ph.D., Vice President, Head of Technology Operations & Analytical & Regulatory CMC and Ed Amat, Vice President of International Sales & Marketing for WuXi AppTec discuss the company’s Laboratory Testing Division.

  4. Addressing Development Challenges for Complex Biologic Drug Candidates

    Karen Fallen, Vice President, Business Unit Head of Clinical Development & Manufacturing at Lonza, discusses how to handle increasingly complex biological candidates.

  5. Differentiating Generic SODFs with Hard Capsule Formulations

    With lower development costs and greater flexibility, hard capsules are the best choice for the formulation of generic solid oral dosage pharmaceuticals, explains Jonathan Gilinski, Executive Director for CapsCanada.

  6. An OEE Approach To Solid Dose Equipment Purchasing and Implementation

    Adam Covitt, Vice President of Federal Equipment Company discusses strategic equipment acquisition.

  7. Groundbreaking for Amgen in Rhode Island

    The $200-million biopharma plant will be completed in 2020.

  8. Quethera Acquired by Astellas Pharma

    Astellas will pay up to £85m in upfront and contingent payments.

  9. Allergan and Editas Medicine Announce Exercise of Options to Jointly Develop CRISPR Genome Editing Experimental Medicine EDIT-101

    EDIT-101 is Editas Medicine's experimental CRISPR genome editing medicine for the treatment of Leber Congenital Amaurosis type 10 (LCA10).

  10. Pliant Therapeutics Receives FDA Orphan Drug Designation for Lead Program PLN-74809 in Idiopathic Pulmonary Fibrosis
    Pliant Therapeutics, Inc., a biotechnology company focused on discovering, developing and commercializing treatments for fibrotic diseases, has been granted orphan drug designation for its anti-fibrotic lead compound, PLN-74809, for the treatment of idiopathic pulmonary fibrosis (IPF).
  11. Building a Robust Supply Chain with Dependable Quality Primary Suppliers

    Drug manufacturers and their suppliers face a number of challenges, such as downward pricing pressures and the need for flexibility and speed to market, says Dale Martin, General Manager & CFO for CapsCanada.

  12. With Expertise Comes Security

    Using a trusted expert to remove surplus equipment helps protect your facility and assets, says Matt Hicks, Chief Operating Officer & Counsel for Federal Equipment Company. 

  13. Death to Cleanrooms in Biopharmaceutical Manufacturing

    Marc Pelletier, Ph.D., Director of CRB USA explains the benefits of closed processing.

  14. Biosimilars: Are We on the Edge of a New Era of Biologics?

    Experts weigh in on our Roundtable question.

  15. Nice Insight Overview: The Key to Pharma’s Next Generation Success

    Evolving markets are prompting drug owners and developers to pursue new business models in the post-blockbuster era.

  16. Behind the Scenes of International Pharmaceutical Business Success: A Conversation with Horst Wallrabe

    Haig Armaghanian is in conversation with Horst Wallrabe, formerly of Bayer, to reflect on his impressive career and what lies ahead.

  17. Grifols Achieves Key Milestone with FDA Approval of the New Consolidated Manufacturing Facility (CMF) for Production of Recombinant Proteins

    The company received approval to relocate existing immunodiagnostic manufacturing operations to a new Consolidated Manufacturing Facility (CMF) in Emeryville, California. 

  18. Xolair Gets Breakthrough Therapy Designation from US FDA for Treatment of Food Allergies
    If approved, the drug would be the first FDA-approved treatment for the prevention of severe reactions due to food allergies.
  19. Perrigo to Divest Its Prescription Drug Business

    Company to focus on generics and consumer products.

  20. Array BioPharma Receives FDA Breakthrough Therapy Designation for BRAFTOVI™ in combination with MEKTOVI® and cetuximab for BRAFV600E-mutant Metastatic Colorectal Cancer

    The designation is based on Phase 3 BEACON CRC safety lead-in data.

Nice Insight Awareness/Perception Scorecard

Research. Compare. Contact. Find the Ideal Partner.

Customer Awareness (CA) describes a buyer’s knowledge of your offering, while Customer Perception (CP) describes how a buyer rates your company based on that knowledge. Nice Insight’s CA/CP scorecard allows you to measure market awareness and perception of you and your industry peers based on acknowledged outsourcing drivers.

  1. Search by company type, region, market segment and services.
  2. Select up to 5 companies to compare.
  3. View CA & CP performance scores against industry benchmark ratings.
SEARCH COMPANIES
Acquisition

Quethera Acquired by Astellas Pharma

Aug 14, 2018 12:21:54 PM PAO-M08-18-NI-018
Facility

Groundbreaking for Amgen in Rhode Island

Aug 14, 2018 12:17:45 PM PAO-M08-18-NI-017
Breakthrough Therapy

Xolair Gets Breakthrough Therapy Designation from US FDA for Treatment of Food Allergies

Aug 14, 2018 12:13:08 PM PAO-M08-18-NI-016
Business

Perrigo to Divest Its Prescription Drug Business

Aug 14, 2018 12:09:57 PM PAO-M08-18-NI-015
Investment

Artios Pharma Receives $84 million in Series B Funding

Aug 14, 2018 12:07:40 PM PAO-M08-18-NI-014
Regulatory

China to Accelerate Review of 48 Foreign Drugs

Aug 14, 2018 12:04:37 PM PAO-M08-18-NI-013
Market Intelligence

Forces Driving Growth in the U.S. Surgical Microscopes Market

Aug 9, 2018 3:58:58 PM PAO-08-18-CL-001
Acquisition

Intertek Groups Expands Offerings with the Acquisition of Alchemy Systems

Aug 9, 2018 1:12:27 PM PAO-M08-18-NI-012
Biologics

New Method Developed for Stereoselective Synthesis of Biologic Drug Substances

Aug 8, 2018 2:11:08 PM PAO-M08-18-NI-011
China

Big Pharma Companies Taking New Drugs to China First

Aug 8, 2018 2:03:21 PM PAO-M08-18-NI-010
CRO

From Internal Lab to External Service Provider

Aug 8, 2018 1:57:27 PM PAO-M08-18-NI-009
Drug Delivery

Exosomes Explored as New Option in Drug Delivery

Aug 7, 2018 3:33:40 PM PAO-M08-18-NI-008
Microbiome

New Collaboration Targets Drug Development Using the Gut Microbiome

Aug 7, 2018 3:12:17 PM PAO-M08-18-NI-007
Columns

Nice Insight Overview

Changes in the  Biopharma Industry: from Minor to Major Evolution
New technologies such as gene editing are leading to the development of even more advanced, targeted medicines.

The Next-Generation Player

Addressing Development Challenges for Complex Biologic Drug Candidates
At Lonza, we are constantly looking to reduce the development timeline, giving our customers more control over their projects.


Karen Fallen, Vice President, Business Unit Head of Clinical Development & Manufacturing Lonza Pharma & Biotech

M+A Column

Inside Mergers & Acquisitions
Kevin Bottomley Partner, Results Healthcare
Deals in the pharmaceutical industry are an important mechanism of acquiring innovation, business and efficiency.

Nice Insight Overview

Doping: Famous Cases, Substances and Values in Sports

Marc Technow, Nice Insight